IN2015DN00598A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00598A
IN2015DN00598A IN598DEN2015A IN2015DN00598A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A IN 598DEN2015 A IN598DEN2015 A IN 598DEN2015A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A
Authority
IN
India
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
embodiment provides
Prior art date
Application number
Other languages
English (en)
Inventor
Roger D Tung
Adam J Morgan
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2015DN00598A publication Critical patent/IN2015DN00598A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN598DEN2015 2012-07-30 2013-07-30 IN2015DN00598A (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677307P 2012-07-30 2012-07-30
PCT/US2013/052721 WO2014022390A1 (en) 2012-07-30 2013-07-30 Deuterated ibrutinib

Publications (1)

Publication Number Publication Date
IN2015DN00598A true IN2015DN00598A (lt) 2015-06-26

Family

ID=48917743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN598DEN2015 IN2015DN00598A (lt) 2012-07-30 2013-07-30

Country Status (13)

Country Link
US (2) US9422295B2 (lt)
EP (1) EP2882751B1 (lt)
JP (1) JP6261580B2 (lt)
KR (1) KR20150038486A (lt)
CN (1) CN104507946A (lt)
AU (1) AU2013296627C9 (lt)
BR (1) BR112015001839A2 (lt)
CA (1) CA2879400A1 (lt)
EA (1) EA201590296A1 (lt)
ES (1) ES2682043T3 (lt)
IN (1) IN2015DN00598A (lt)
MX (1) MX2015001246A (lt)
WO (1) WO2014022390A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022390A1 (en) 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN103965201A (zh) * 2014-04-30 2014-08-06 淮海工学院 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法
CN104945404B (zh) * 2014-06-25 2018-09-14 广东东阳光药业有限公司 一种n-丙烯羰基哌啶衍生物的制备方法
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN107207519B (zh) * 2015-02-12 2019-11-08 正大天晴药业集团股份有限公司 伊布替尼的制备方法
WO2016132383A1 (en) * 2015-02-18 2016-08-25 Mylan Laboratories Limited Process for the preparation of ibrutinib
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016151438A1 (en) * 2015-03-20 2016-09-29 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
KR20190003711A (ko) 2016-05-04 2019-01-09 콘서트 파마슈티컬즈, 인크. 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US11384062B2 (en) 2017-04-04 2022-07-12 Combiphos Catalysts, Inc. Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希(南京)药物研发有限公司 一种依鲁替尼-d5的制备方法
CN112876484B (zh) * 2020-08-31 2022-06-28 绍兴舜邦医药科技有限公司 一种氘代依鲁替尼的制备方法
CN112125913B (zh) * 2020-10-29 2024-07-19 瑞阳制药股份有限公司 高纯度伊布替尼的合成方法
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2024109676A1 (zh) * 2022-11-21 2024-05-30 天津征程医药科技有限公司 具有btk抑制作用的吡唑并嘧啶衍生物
CN118063429A (zh) * 2022-11-23 2024-05-24 天津瑞程健达医药科技有限公司 作为btk抑制剂的吡啶酰胺类化合物
CN118307541A (zh) * 2023-01-09 2024-07-09 天津济坤医药科技有限公司 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
DE10155018A1 (de) * 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2201840B1 (en) * 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US9212285B2 (en) 2012-02-08 2015-12-15 Council Of Scientific & Industrial Research Electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste
WO2014022390A1 (en) 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib

Also Published As

Publication number Publication date
MX2015001246A (es) 2015-04-10
US9422295B2 (en) 2016-08-23
US9777009B2 (en) 2017-10-03
EP2882751A1 (en) 2015-06-17
EA201590296A1 (ru) 2015-07-30
US20150210699A1 (en) 2015-07-30
US20170015670A1 (en) 2017-01-19
JP2015528020A (ja) 2015-09-24
AU2013296627C9 (en) 2018-03-22
AU2013296627C1 (en) 2016-12-15
KR20150038486A (ko) 2015-04-08
BR112015001839A2 (pt) 2017-07-04
JP6261580B2 (ja) 2018-01-17
WO2014022390A1 (en) 2014-02-06
AU2013296627B2 (en) 2016-07-14
ES2682043T3 (es) 2018-09-18
CN104507946A (zh) 2015-04-08
EP2882751B1 (en) 2018-06-27
AU2013296627A1 (en) 2015-02-05
CA2879400A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
IN2015DN00598A (lt)
MX2015002040A (es) Baricitinib deuterado.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
IN2015DN00960A (lt)
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
JO3318B1 (ar) مثبطات bace
IN2014DN07996A (lt)
MX2015008829A (es) Momelotinib deuterado.
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
IN2014DN10669A (lt)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012610A (es) Pacritinib deuterizado.
EA201690593A1 (ru) Новые соединения мочевины
IN2013CH05395A (lt)
MX2015001134A (es) Compuestos terapeuticos.
UA72478U (ru) Применение полентара как средства фригопротекторного действия